Heart failure (HF) affects at least 26 million people worldwide, and the prevalence is increasing year by year. HF patients experience a high burden of symptoms and functional limitations, and morbidity and mortality remain high despite successful therapies \[[@CR1]\]. Type 2 diabetes mellitus (T2DM), the most frequent subtype of diabetes, is an expanding global health problem \[[@CR2]\], and in the past decades, the global prevalence has increased by 30%, and now about 463 million people are affected. Both HF and T2DM independently increase the morbidity of another disease and associated with considerable mortality \[[@CR3], [@CR4]\]. There are many glucose-lowering agents used in patients with HF \[[@CR5]\], however, the results are mixed \[[@CR6]\]. Here, we critically and systematically explored the effect of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on the treatment of patients with HF.

We included all perticipants from the Functional Impact of GLP-1 for Heart Failure Treatmen (FIGHT) \[[@CR7]\] and Effect of Liraglutide on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes (LIVE) \[[@CR8]\] trials, which are multicentre, double-blind, randomised, placebo-controlled clinical trial. Two reviewers extracted data independently and crossed check. Only data indicators from both trials can be used for subsequent analysis. All the results were descriptive analysis.

In those trials, 541 perticipants from 24 sites in the United States and 4 Danish Centres were included. The baseline of two trials was basically similar, regardless of general data, functional measures, physical examination, medical history, laboratory measures, echocardiographic data, and HF medications (Table [1](#Tab1){ref-type="table"}). The outcomes of FIGHT and LIVE are not exactly the same, and we choose the coincident indicators for analysis. In FIGHT, liraglutide decreased left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, hemoglobin A1c and heart rate, and increased left ventricular end-systolic volume index, left ventricular end-diastolic volume index, and 6 min walk test, compared with placebo. However, there was no statistical difference. In LIVE, liraglutide significantly decreased hemoglobin A1c (*P* \< 0.0001) and inceased 6 min walk test (*P* = 0.04) and heart rate (*P* \< 0.0001), compared with placebo. There were no statistical differences in the influence of the abovementioned outcomes that coincided with FIGHT (Table [1](#Tab1){ref-type="table"}).Table 1The details of FIGHT and LIVE trialsFIGHTLIVELiraglutide (N = 154)Placebo (N = 146)Liraglutide (N = 122)Placebo (N = 119)Genaral data Age62 (52--68)61 (51--67)65 ± 9.265 ± 10.7 Male123 (80%)113 (77%)109 (89%)106 (89%) BMI (kg/m^2^)31 (26--36)33 (25--38)28.0 ± 3.829.8 ± 4.6Functional measures 6MWT (m)234 (143--313)212 (141--311)453 ± 104441 ± 122NYHA I4 (3%)8 (5%)36 (30%)35 (29%) II49 (32%)36 (25%)65 (53%)64 (54%) III93 (60%)96 (66%)17 (14%)16 (13%) IV8 (5%)6 (4%)4 (3%)4 (3%)Physical examination SBP108 (99--120)108 (99--118)128 ± 20127 ± 18 HR75 (68--85)76 (68--88)67 ± 1067 ± 11Medical history T2DM91 (59%)87 (60%)39 (32%)35 (29%) AF74 (48%)70 (48%)34 (28%)34 (29%) Ischemic heart disease133 (86%)113 (77%)72 (59%)73 (61%)Laboratory measures NT-proBNP (pg/mL)1936 (1075--4231)2083 (1020--4333)413 (208--926)388 (153--880) HbA1c (%)6.6 (6.6--7.6)6.7 (5.9--7.9)5.9 ± 0.76.0 ± 0.8Echocardiographic data LVEF (%)25 (20--33)25 (19--32)33.7 ± 7.635.4 ± 9.4 LVESV (mL)104 (78--130)100 (80--1330111 ± 60109 ± 78 LVEDV (mL)140 (112--173)137 (115--174)163 ± 71165 ± 111 E/e\'22 (17--28)23 (18--30)12.6 ± 6.011.7 ± 5.5Heart failure medications ACEI/ARB112 (73%)104 (71%)118 (97%)115 (97%) β-Blocker143 (93%)139 (95%)113 (93%)108 (91%) Aldosterone recepter antagonist88 (57%)89 (61%)59 (48%)54 (45%) Loop diuretic151 (98%)146 (100%)90 (74%)90 (76%) Lipid-lowering agent110 (71%)110 (75%)96 (79%)92 (77%)Treatmen effect LVEF − 0.1 (− 2.3--2.1) − 0.8 (− 2.1--0.5) LVESV5 (− 2.6--12.7)2.6 (− 1.2--6.4) LVEDV6.7 (− 2.6--16)3.4 (− 2.3--9.2) 6MWT5 (− 29--39)24 (2--47) NT-proBNP (pg/mL) − 155 (− 1368--1058)− 140 (− 317--37) HbA1c (%) − 0.33 (− 0.67--0) − 0.4 (− 0.5-- − 0.3) HR − 1.6 (− 4.8--1.6)7 (5--9)*FIGHT* Functional Impact of GLP-1 for Heart Failure Treatmen, *LIVE* Effect of Liraglutide on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes, *BMI* body mass index, *6MWT* 6-min walk test, *NYHA* New York Heart Association, *SBP* systolic blood pressure, *HR* heart rate, *T2DM* type 2 diabetes mellitus, *AF* atrial fibrillation, *NT-proBNP* N-terminal pro-B-type natriuretic peptide, *HbA1* chemoglobin A1c, *LVEF* left ventricular ejection fraction, *LVESV* left ventricular end-systolic volume index, *LVEDV* left ventricular end-diastolic volume index, *E/e\'* ratio of early mitral inflow velocity to early diastolic medial mitral annular velocity, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker

In LEADER, the rate of the primary composite outcome in the time-to-event analysis (the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke) among patients with T2DM and high cardiovascular risk was lower with liraglutide than with placebo, whereas the number of hospitaion for HF was reduced non-significantly in the active arm \[[@CR9]\]. The encouraging results of this study may only indicate the potential strong benefits of liraglutide for diabetic patients with high cardiovascular risk. In our study, we specifically included patients with demonstrated HF, not with high cardiovascular risk, to evaluate the effectiveness and safety of liraglutide, and we concluded that liraglutide may be helpful for patients with HF. After careful investigation, we found that the results of FIGHT and LIVE were not identical. The reasons may be various. Firstly, the prescription of liraglutide is different. Liraglutide dosage uptitration as tolerated every 14 days from 0.6 to 1.2 to 1.8 mg/d during the first 30 days of the FIGHT trial, whereas subcutaneous injectable liraglutide was introduced at a dose of 0.6 mg/day, which was increased to 1.2 mg/day after 1 week and to 1. 8 mg/day thereafter in the LIVE trial. Although a dose increase could be postponed depending on the patient\'s tolerance to the trial product or reduced at any time during the trial if required, different administration of liraglutide may also have an impact on the results. For later trials, we may need a unified way of liraglutide dosing. The second may be recommended because it is consistent with LEADER \[[@CR9], [@CR10]\]. Secondly, though HF with left ventricular ejection fraction \< 45% was included, it was clear that the degree of HF in FIGHT was more severe than that in LIVE, because it was dominated by New York Heart Association Class II and III (90%). Additionally, two studies were conducted in different country, which may result in excursion in race. Finally, results from LIVE indicated that treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events. More data on the safety of liraglutide in patients with HF are needed.

In this study, we found that there is not enough reason to support the use of liraglutide in patients with HF, which is consistent with the latest updated meta-analysis of 43 randomized controlled trials \[[@CR11]\]. Another a network meta-analysis of 171,253 participants from 91 randomized controlled trials also showed that GLP-1 analogue was significantly inferior to sodium-glucose co-transporters 2 inhibitors in terms of HF risk \[[@CR12]\]. Among patients with HF and T2DM, after adjusting for baseline characteristics and disease risk factors, the use of GLP-1 analogue was associated with higher risk of HF hospitalization compared to dipeptidyl peptidase-4 inhibitors, though the association was not statistically significant \[[@CR13]\]. In the spontaneously developed HF model of J2N-k hamsters, liraglutide exerted further deteriorated cardiac function with overt fibrosis and cardiac enlargement \[[@CR14]\]. However, clinical evidences showed that liraglutide reduced early left ventricular diastolic filling and left ventricular filling pressure, thereby unloading the left ventricle \[[@CR15], [@CR16]\]. Renal dysfunction is often associated with HF. Interestingly, liraglutide was not associated with excess risk of worsening renal function compared with placebo \[[@CR17]\], result from post hoc analysis of FIGHT, supporting the relative renal safety profile of liraglutide among patients with HF. Additionaly, GLP-1 analogue reveals cardiovascular and renal protective effects, although this effect is not as evident as sodium-glucose co-transporters 2 inhibitor \[[@CR18], [@CR19]\].

In summary, the results of the body of existing evidence do not support the use of liraglutide in HF. Importantly, the safety of liraglutide in this particular population remains uncertain. Therefore, further studies are needed to assess the risks and benefits of liraglutide in patients with HF.
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